{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:09:30Z","timestamp":1782230970895,"version":"3.54.5"},"reference-count":39,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,3,31]]},"DOI":"10.2217\/fon-2018-0659","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T12:58:03Z","timestamp":1547470683000},"page":"967-977","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Cobimetinib in Malignant Melanoma: How to MEK an Impact on Long-Term Survival"],"prefix":"10.1080","volume":"15","author":[{"given":"Alice","family":"Indini","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Tondini","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2003.12.008"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.024"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3392"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7888"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.023"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043778"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0445"},{"key":"e_1_3_3_18_1","unstructured":"Cotellic\u00ae (cobimetinib) prescribing information. Genentech Inc. South San Francisco CA USA (2015)."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2016.132"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1389-z"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2479"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2023"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04304"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70024-X"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30180-8"},{"issue":"15","key":"e_1_3_3_28_1","article-title":"A first-in-human Phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors","volume":"30","author":"LoRusso P","year":"2012","unstructured":"LoRusso P , ShapiroG, PandyaSSet al. A first-in-human Phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J. Clin. Oncol.30(15 Suppl.), Abstract 2566 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400383x"},{"issue":"8","key":"e_1_3_3_30_1","article-title":"Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase I study","volume":"71","author":"Musib L","year":"2011","unstructured":"Musib L , EpplerS, ChooEet al. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase I study. Cancer Res.71(8 Suppl.), Abstract 1304 (2011).","journal-title":"Cancer Res."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70301-8"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9036"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024"},{"issue":"2","key":"e_1_3_3_35_1","article-title":"LBA-01: safety and efficacy of cobimetinib and atezolizumab in a Phase Ib study of metastatic colorectal cancer","volume":"27","author":"Bendell J","year":"2016","unstructured":"Bendell J , KimTW, CheeCEet al. LBA-01: safety and efficacy of cobimetinib and atezolizumab in a Phase Ib study of metastatic colorectal cancer. Ann. Oncol.27(Suppl. 2), Abstract (2016).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx040"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0456"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.01.003"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu169"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.06.018"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3122"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:12Z","timestamp":1719125112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,3,31]]}},"alternative-id":["10.2217\/fon-2018-0659"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0659","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}